ContractAbivax S.A. • September 29th, 2023 • Pharmaceutical preparations
Certain information has been excluded from this agreement (indicated by “[***]”) because such information is both not material and the type that the registrant treats as private or confidential.
SUBSCRIPTION AGREEMENT By and between Abivax S.A. as Issuer and Kreos Capital VII (UK) Limited Kreos Capital VII Aggregator SCSp Claret European Specialty Lending Company III, S.à r.l. Claret European Growth Capital Fund III SCSp As SubscribersSubscription Agreement • September 29th, 2023 • Abivax S.A. • Pharmaceutical preparations
This subscription agreement (hereinafter referred to as the “Subscription Agreement”) is entered into on 20 August 2023, by and between:
ContractDrug Discovery Services Agreement • September 29th, 2023 • Abivax S.A. • Pharmaceutical preparations
Certain information has been excluded from this agreement (indicated by “[***]”) because such information is both not material and the type that the registrant treats as private or confidential.
ContractAbivax S.A. • September 29th, 2023 • Pharmaceutical preparations
Certain information has been excluded from this agreement (indicated by “[***]”) because such information is both not material and the type that the registrant treats as private or confidential.
ContractAbivax S.A. • September 29th, 2023 • Pharmaceutical preparations
Certain information has been excluded from this agreement (indicated by “[***]”) because such information is both not material and the type that the registrant treats as private or confidential.
ContractAbivax S.A. • September 29th, 2023 • Pharmaceutical preparations
Certain information has been excluded from this agreement (indicated by “[***]”) because such information is both not material and the type that the registrant treats as private or confidential.
ContractAbivax S.A. • September 29th, 2023 • Pharmaceutical preparations
Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.
ContractAbivax S.A. • September 29th, 2023 • Pharmaceutical preparations
Certain information has been excluded from this agreement (indicated by “[***]”) because such information is both not material and the type that the registrant treats as private or confidential.
ABIVAX SA EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • November 19th, 2024 • Abivax S.A. • Pharmaceutical preparations • New York
As further set forth in this equity distribution agreement (this “Agreement”), Abivax SA, a société anonyme organized under the laws of the French Republic and registered with the Register of Commerce and Companies (Registre du Commerce et des Sociétés) of Paris under number 799 363 718 (the “Company”), proposes to offer and sell from time to time through Piper Sandler & Co. (the “Agent”), as sales agent, American Depositary Shares (“ADSs”), each representing one of the ordinary shares, nominal value of €0.01 per share, of the Company (the “Ordinary Shares”), and collectively having an aggregate gross sales price not to exceed $150,000,000 (such ADSs to be sold pursuant to this Agreement, the “Placement ADSs”) on terms set forth herein. The Ordinary Shares underlying the Placement ADSs (the “Underlying Shares”) are to be deposited pursuant to a deposit agreement (the “Deposit Agreement”), dated as of October 24, 2023, as may be amended from time to time, among the Company, Citibank, N.
⚫ ] Ordinary Shares and [ ⚫ ] American Depositary Shares, Each Representing One Ordinary Share (Nominal Value €0.01 per Share) ABIVAX SA UNDERWRITING AGREEMENTUnderwriting Agreement • October 18th, 2023 • Abivax S.A. • Pharmaceutical preparations • New York
ContractAbivax S.A. • September 8th, 2023 • Pharmaceutical preparations
Certain information has been excluded from this agreement (indicated by “[***]”) because such information is both not material and the type that the registrant treats as private or confidential.
ContractIssue Agreement • September 8th, 2023 • Abivax S.A. • Pharmaceutical preparations
Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.
MASTER SERVICES AGREEMENTMaster Services Agreement • September 8th, 2023 • Abivax S.A. • Pharmaceutical preparations
This Master Services Agreement (“Agreement”) effective as of 17th December, 2018 (“Effective Date”) is made between ABIVAX SA which has a place of business at 5, rue de la Baume—F-75008 Paris—France (“Sponsor”) and IQVIA Ltd of 500 Brook Drive, Green Park, Reading, Berkshire RG2 6UU (“IQVIA”). When signed by both parties, this Agreement will set forth the terms and conditions under which IQVIA agrees to provide certain services to Sponsor as set forth herein.
Dated 20 August 2023 Subscription Agreement €35,000,000 Amortizing Senior Notes Convertible into New Shares of Abivax due 2027 (the “Tranche A Notes”) and Up to €40,000,000 Amortizing Senior Notes Convertible into New Shares of Abivax (the “Tranche(s)...Subscription Agreement • September 8th, 2023 • Abivax S.A. • Pharmaceutical preparations
ContractWarrants Issue Agreement • September 8th, 2023 • Abivax S.A. • Pharmaceutical preparations
Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.
ContractAbivax S.A. • September 29th, 2023 • Pharmaceutical preparations
Certain information has been excluded from this agreement (indicated by “[***]”) because such information is both not material and the type that the registrant treats as private or confidential.
ContractOcabsa Issue Agreement • September 8th, 2023 • Abivax S.A. • Pharmaceutical preparations
Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.
TRANCHE A-B PUT OPTION AGREEMENT BSA2023-KC-AB By and between Abivax S.A. as Issuer and Kreos Capital VII Aggregator SCSp Claret European Growth Capital Fund III SCSp as BeneficiariesPut Option Agreement • September 8th, 2023 • Abivax S.A. • Pharmaceutical preparations
